Amine Segueni, MD
Internal Medicine · Matthews, NCNPI 1144461054
Payments from drug & device makers
Across 90 payments — averaging $1351.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$120K
- Lilly USA, LLC$213
- Novo Nordisk$119
- Abbott$95
- Merck$91
- Pfizer$89
- plus $825 from 19 others
What the payments were for
- Travel & lodging$68227%
- Food & beverage$1,81873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $120,211 |
| Lilly USA, LLC | 12 | $213 |
| Novo Nordisk | 6 | $119 |
| Abbott | 5 | $95 |
| Merck | 4 | $91 |
| Pfizer | 5 | $89 |
| Amgen | 5 | $81 |
| Exact Sciences | 4 | $80 |
| GSK | 4 | $77 |
| Sumitomo Pharma America, Inc. | 3 | $68 |
| Astellas Pharma US Inc | 3 | $65 |
| Phathom Pharmaceuticals, Inc. | 3 | $58 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| AstraZeneca | 3 | $48 |
| Johnson & Johnson | 2 | $45 |
| Boehringer Ingelheim | 2 | $38 |
| Masimo Corporation | 2 | $34 |
| AbbVie | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Mayne Pharma Commercial LLC | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Phadia US Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$121,643 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 97 | $102,844 |
| FarxigaDapagliflozin Propanediol | 87 | $82,850 |
| OzempicSemaglutide | 48 | $78,745 |
| JardianceEmpagliflozin | 50 | $73,434 |
| MounjaroTirzepatide | 38 | $56,088 |
| MyrbetriqMirabegron | 42 | $31,984 |
| XareltoRivaroxaban | 18 | $20,609 |
| GemtesaVibegron | 15 | $19,510 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $14,610 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $14,352 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 55 | $12,135 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 25 | $7,825 |
| Atorvastatin Calcium | 466 | $4,044 |
| Rosuvastatin Calcium | 359 | $3,637 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $89 | $102,84497 claims |
| AstraZenecaFarxiga | $48 | $82,85087 claims |
| Novo NordiskOzempic | $119 | $78,74548 claims |
| Boehringer IngelheimJardiance | $38 | $73,43450 claims |
| Lilly USA, LLCMounjaro | $213 | $56,08838 claims |
| GSKBreo Ellipta, Shingrix, Arexvy, Arnuity Ellipta | $77 | $37,494129 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $31,98442 claims |
| Johnson & JohnsonXarelto | $45 | $20,60918 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $68 | $19,51015 claims |
| MerckJanumet Xr | $91 | $14,61014 claims |
| AbbVieSynthroid | $34 | $2,12829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Matthews
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.